Search PubMed⌕ Search

Biomedical subjects

L A Runge

Publications and source records attributed to L A Runge.

6 recordsLinked to original sources
PubMed1986

High IgM antibody to human T-lymphotropic virus type I in systemic lupus erythematosus.

Twenty-six percent of 53 systemic lupus erythematosus sera had high levels of IgM antibody to human T-lymphotropic virus Type I, significantly more than the 5% of normal controls. Neither IgG antibodies to Type I virus nor IgM or IgG antibodies to Type II virus were increased in lupus. Further analysis using competition immunoassay and Western blot techniques also suggested that the IgM Type I antibodies in lupus sera were directed against viral antigens but did not completely exclude a nonviral reaction. Other studies also have not found IgG antibodies to the Type I virus but have not tested for IgM antibodies. Our study suggests that human T-lymphotropic virus Type I or a related virus may be involved in the pathogenesis of some cases of systemic lupus erythematosus.

Adolescent↗
PubMed1979

Treatment of rheumatoid arthritis with levamisole: long-term results and immune changes.

We treated 29 rheumatoid arthritis patients with levamisole. on the basis of a 25% improvement in any 3 of 6 measurements 95% of the patients had a favourable response within 20 weeks. However, 64% of the patients discontinued levamisole by 40 to 60 weeks because of rash or secondary treatment failures. Delayed skin reactivity to streptokinase-streptodornase increased significantly in the entire treatment group, but there was in inverse correlation between skin test enhancement and clinical response. There was no overall change in lymphocytes response to phytohaemagglutinin (PHA) after 4 and 16 weeks of treatment, but seven patients with enhanced lymphocyte responsiveness to PHA experienced an earlier clinical response to levamisole. Treatment with levamisole frequently results in clinical improvement in rheumatoid arthritis, but this is not clearly related to a stimulatory effect on cell-mediated immunity. Its long-term usefulness may be limited by a high incidence of relapse and rash.

Arthritis, Rheumatoid↗
PubMed1976

Search for antigen in rheumatoid synovial macrophages.

Peripheral blood monocytes and synovial macrophages obtained from 21 patients with rheumatoid arthritis and from 13 controls were cultured with autologous peripheral blood lymphocytes and stimulation measured by thymidine uptake. Rheumatoid macrophages and monocytes induced a small but significant degree of lymphocyte transformation, and those from the controls did not. The degree of stimulation appears to be more consistent with the nonspecific effect of lymphocyte activating factor, rather than with the presence of a specific synovial antigen.

Antigens↗
PubMedDate not supplied

Treatment of rheumatoid arthritis with levamisole. A controlled trial.

Levamisole, an anthelminthic agent with immunostimulatory properties, was used in a double-blind, controlled therapeutic trial in rheumatoid arthritis. Patients received either levamisole 100 mg 4 days a week, or placebo, for a period of 4 months. Significant improvement in the treated group, as compared with the control group, was found in the number of tender and swollen joints, grip strength, range of joint motion, sedimentation rate, and C-reactive protein. On double-blind global evaluation by the examining physicians, 9 of 14 patients on levamisole and none of 13 on placebo were considered to have improved. Adverse effects did not differ in frequency between the two groups except for mild alteration in taste, which was more common with levamisole.

Arthritis, Rheumatoid↗